DAX22.840 -2,8%Est505.614 -2,1%MSCI World4.343 -0,1%Top 10 Crypto9,4100 -2,0%Nas22.091 -0,3%Bitcoin60.658 -2,4%Euro1,1580 ±0,0%Öl108,7 -0,9%Gold4.645 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Vonovia A1ML7J Rheinmetall 703000 Siemens Energy ENER6Y SAP 716460 NVIDIA 918422 Lufthansa 823212 DroneShield A2DMAA Volkswagen (VW) vz. 766403 Deutsche Telekom 555750 Allianz 840400 Infineon 623100 Micron Technology 869020 Shell (ex Royal Dutch Shell) A3C99G Deutsche Bank 514000 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Zinsentscheid: DAX schließt tiefrot -- Wall Street schwach -- Micron-Zahlen: Gewinn vervielfacht -- Equinor, Rivian, Uber, Samsung, Rüstungsaktien, Siemens Energy, Tesla, NVIDIA, BYD im Fokus
Top News
Kommt die Cerebras-Aktie im April? NVIDIA-Herausforderer vor Börsengang unter der Lupe Kommt die Cerebras-Aktie im April? NVIDIA-Herausforderer vor Börsengang unter der Lupe
Die 10.000-Dollar-Prognose: Warum ein Experte den Bitcoin vor einem Mega-Crash sieht Die 10.000-Dollar-Prognose: Warum ein Experte den Bitcoin vor einem Mega-Crash sieht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Pacira Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
19,50 EUR +0,37 EUR +1,94 %
BMN
22,56 USD +0,53 USD +2,41 %
BTT
finanzen.net zero
Pacira Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.778,07 Mio. EUR

KGV165,69Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1H68T

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6951271005

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPCRX

Pacira Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireDOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
PR NewswireDOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
Wer­bungPacira Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireInvestors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
PR NewswireLawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation
PR NewswireDOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
PR NewswireDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswirePCRX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In PCRX To Contact Him Directly To Discuss Their Options
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswirePCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireShareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
PR NewswireThe Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
PR NewswirePCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireInvestors who lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX
PR NewswirePacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
PR NewswirePCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswirePCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PR NewswireDOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireDOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
PR NewswireG.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

Pacira Pharmaceuticals News

Pacira Pharmaceuticals News: auf dieser Seite finden Sie alle Pacira Pharmaceuticals News und Nachrichten zur Pacira Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pacira Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pacira Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.